USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ONCOTECH, INC.
Address:
ONCOTECH, INC.
1791 KAISER AVE
IRVINE, CA 92614
Phone:
(949) 474-9262
URL:
N/A
EIN:
330141150
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $349,354.00 5

Award List:

THE LONG-TERM GOAL OF THIS PROJECT IS THE DEVELOPMENT OF NEWTHERAPEUTIC STRATEGIES FOR THE CIRCUMVENTION OF DRUG RESISTANCE IN HUMAN NEOPLASMS.

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Robert nagourney , PRINCIPAL INVESTIGATOR
Abstract:
The long-term goal of this project is the development of newtherapeutic strategies for the circumvention of drug resistance in human neoplasms. by first establishing the ability of the differential staining cytotoxicity assay to detect and circumvent drug resistance, the project will lay the… More

Development of a Therapeutic TNF Degradation Product

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
John P. Fruehauf
Abstract:
Recombinant human tumor necrosis factor-alpha (TNF) has had only modest success in clinical trials, in part because of dose limiting toxicities. To fully realize TNF's clinical activity, it will be necessary to develop more potent TNF analogues possessing fewer untoward effects. Several studies have… More

Development of an MDR-1 Resistance-Reversal Assay

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
John P. Fruehauf
Abstract:
Currently, assays for MDR-1 expression are for research purposes only. This study will determine if measurement of MDR-1 expression by flow cytometry can be performed as a routine clinical assay, and if such an assay can predict the clinical response of patients treated with Taxol for ovarian… More

A New High Throughput Assay for Human MDR1 Substrates

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$99,653.00
Agency:
HHS
Principal Investigator:
Eugene Mechetner
Abstract:
DESCRIPTION (PROVIDED BY APPLICANT): We propose to develop and validate a high throughput assay for cost/time-efficient screening and characterizing of compounds transported by human MDR1 P-glycoprotein (Pgp). The test (referred to as "the UIC2 Shift Assay") is based on a new… More

GENOMICS SCREENING FOR ANTIANGIOGENESIS DRUGS

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$99,701.00
Agency:
HHS
Principal Investigator:
John P. Fruehauf
Abstract:
DESCRIPTION (provided by applicant): We will develop a system for testing new anti-angiogenesis compounds using vascular endothelial cells (VEC) derived from fresh human tumors. In Phase I we will validate the proposed protocol by correlating the DNA microarray data with current information on… More